REPLY
15.5.2024 14:01:32 CEST | Business Wire | Press release
Reply, with its company WM Reply, has collaborated with Microsoft to fully harness and promote the capabilities of Microsoft 365 Copilot and will showcase its transformative potential at the Milan 2024 Xchange event on May 15-16 through a live immersive experience.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240515336953/en/
Reply, with its company WM Reply, has collaborated with Microsoft to fully harness and promote the capabilities of Microsoft 365 Copilot. As a partner in Microsoft’s Early Access Program (EAP), Reply has leveraged its extensive experience and insights to assist organisations in achieving early successes with Copilot. This collaboration aims to tailor Copilot solutions to specific business needs, from automating routine tasks and enhancing data security to accelerating app development and improving collaboration. (Graphic: Business Wire)
As a partner in Microsoft’s Early Access Program (EAP), Reply has leveraged its extensive experience and insights to assist organisations in achieving early successes with Copilot. This collaboration aims to tailor Copilot solutions to specific business needs, from automating routine tasks and enhancing data security to accelerating app development and improving collaboration. A tailored roadmap, developed in collaboration with Microsoft, guides organisations through the implementation and maximisation of Copilot’s capabilities.
Understanding the importance of adoption, Reply has developed a five-step approach to ensure that the benefits of Copilot M365 are accessible to a wide corporate audience. This approach aligns with Microsoft AI Lab’s vision and focuses on integrating Copilot into daily operations effectively. The below Copilot maturity model framework aims to help customers assess their current state and their desired state with Copilot, and to identify the gaps and the actions needed to achieve their goals:
- Approach – Exploring the art of the possible, technical readiness and align with company strategy.
- Assess – Plan a pilot where we take the early-adopters on a journey with measurement qualitative and quantitative. Use those results to create a business case and roll-out plan.
- Adopt – Set-up a CoE for Copilot. Land key messages and provide training using a scenario/functional specific approach.
- Embed – Make Copilot Business as Usual at or your organisation. Manage a dynamic licensing approach and stay on top of new features.
- Extend – Bring the power of copilot to wider application.
Immersive Introduction at Milan Xchange
Held annually, Reply’s Xchange brings together technology leaders and innovators to explore the latest in digital solutions and strategies. This year, Reply will debut the “AI-Scape Room," an immersive virtual escape room experience developed by WM Reply and powered by Microsoft Copilot for Microsoft 365. This demonstration will highlight how Copilot enhances productivity, security, and collaboration within business processes through advanced AI integration.
The AI-Scape Room is designed to foster teamwork and communication as participants collaborate to solve puzzles and challenges with the assistance of Copilot’s AI-driven insights. The bespoke escape room is an opportunity for all participants to experience, explore and discover how to utilise M365 copilot as the hands-on challenges provide valuable insights into the potential of AI in enhancing workplace efficiency and engagement.
For more information on Reply’s M365 Copilot Adoption approach, the AI-Scape Room and Reply's AI-based solutions, visit: www.reply.com
Reply
Reply [EXM, STAR: REY] specialises in the design and implementation of solutions based on new communication channels and digital media. As a network of highly specialised companies, Reply defines and develops business models enabled by the new models of AI, big data, cloud computing, digital media and the internet of things. Reply delivers consulting, system integration and digital services to organisations across the telecom and media; industry and services; banking and insurance; and public sectors. www.reply.com
WM REPLY
WM Reply is the Reply Group company specialising in improving employees day-to-day lives through modern workplace solutions and connecting consumers to products and experiences they love online. We support our clients from beginning to end; designing and building their solution and easing adoption. Making sure our clients are not just enjoying the benefits of the cloud but exploiting them as well. We are recognised as leaders within Sitecore, Dynamics 365, Office 365 and the products within such as SharePoint, Power Platform, Yammer and Microsoft Teams. A Microsoft Gold Partner five times over! We have a colourful team who are famous for their imagination, delivery, passion for technology and most importantly, their pride in delivery. www.wm.reply.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240515336953/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release
Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom